For more information call (888) LUHS-888.
Patients must be age = 18 years, and have the following: advanced disease, histologically assessed as RCC, with a component of clear cell histology; measurable metastatic disease that can be monitored throughout the course of the study participation per RECIST 1.1; patients who are candidates for a first-line therapy initiating with sunitinib -Time from diagnosis to treatment
life expectancy of 6 months or greater;
resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade = 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
You are being asked to participate in this study because you have newly diagnosed advanced kidney cancer and you have previously consented to allow for collection of your tumor sample, which may be used to make a personalized experimental drug for you called AGS-003.